TRT Claims Decoded: Evidence vs Marketing in Testosterone Therapy

Why TRT Claims Demand Scrutiny

Testosterone replacement therapy (TRT) has become increasingly commercialized, with direct-to-consumer marketing making extraordinary claims about sexual function, muscle gain, energy restoration, and cognitive enhancement. As a physician, I see patients arriving with expectations shaped by marketing rather than evidence. This requires clear-eyed evaluation: what does TRT actually do, and for whom?

The Testosterone Axis: Basic Mechanism

Testosterone operates through a feedback loop. The hypothalamus secretes GnRH (gonadotropin-releasing hormone), which signals the pituitary to release LH and FSH. LH stimulates Leydig cells in the testes to produce testosterone. When blood testosterone rises, negative feedback suppresses GnRH and LH.

Exogenous TRT bypasses this axis. You're adding testosterone directly, which suppresses endogenous production via feedback inhibition. This is critical: TRT doesn't restore your natural system—it replaces it. Discontinuation after prolonged therapy requires recovery time (weeks to months) for the HPTA (hypothalamic-pituitary-testicular axis) to restart.

What TRT Actually Does: Evidence Base

Sexual Function: The data is real but limited. Meta-analyses show TRT improves erectile function in hypogonadal men (testosterone <300 ng/dL), particularly those with baseline ED. Effect sizes are moderate. For men with normal baseline testosterone, adding more produces minimal additional benefit—this is not linear.

Muscle Mass: TRT increases lean mass in hypogonadal men, roughly 3–7 lbs over 12 weeks. Effect requires resistance training; TRT alone doesn't build muscle. The dose-response is non-linear: therapeutic replacement shows benefit; supraphysiologic doses produce more gain but at escalating cardiovascular and hepatic risk.

Energy and Mood: These improve most dramatically in men with symptomatic hypogonadism (fatigue, depression, low libido plus low testosterone). Placebo effect is substantial. In eugonadal men or mild hypogonadism, benefit is marginal.

What the Marketing Doesn't Say

1. Baseline testing is mandatory. You cannot evaluate TRT efficacy without knowing pre-treatment testosterone, estradiol, hematocrit, lipids, PSA, and liver/kidney function. "Powerful TRT" marketed without baseline bloodwork is reckless.

2. Dose matters enormously. Therapeutic dosing (125–200 mg/week testosterone enanthate, maintaining 500–900 ng/dL) carries lower risk. Supraphysiologic dosing (>300 mg/week, achieving >1000 ng/dL) increases:

   • Polycythemia (elevated hematocrit; thrombotic risk)
   • Gynecomastia (requires aromatase inhibitors; adds complexity)
   • Lipid dysfunction (lower HDL, elevated triglycerides)
   • Hepatic strain
   • Cardiovascular stress (though causality remains debated)

3. ED medication isn't synergistic magic. Marketing TRT bundled with PDE5 inhibitors (sildenafil, tadalafil) suggests they work together. They don't—they address different mechanisms. PDE5 inhibitors work in phosphodiesterase pathways; testosterone works endocrinologically. If you need both, each independently indicates a problem. This isn't "powerful"; it's masking underlying vascular or hormonal dysfunction.

Critical Labs Before and During TRT

Order before starting:

• Total testosterone, free testosterone (calculated or dialysis)
• Estradiol (sensitive assay)
• SHBG (sex hormone-binding globulin—affects free testosterone calculation)
• LH, FSH (to assess baseline axis function)
• Hematocrit, hemoglobin
• Lipid panel (fasting)
• PSA, DRE
• Liver function (AST, ALT, bilirubin)
• Kidney function (creatinine, eGFR)
• Thyroid panel (TSH, free T3, free T4)—hypothyroidism mimics hypogonadal symptoms

Monitor every 6–8 weeks initially, then quarterly:

• Total and free testosterone
• Estradiol
• Hematocrit
• Lipids (6-month intervals)
• PSA (annually)

The Synergy Question

Supplement synergy with TRT is overstated in marketing. Here's what has evidence:

• Zinc & magnesium glycinate: Support natural testosterone production; less relevant once on TRT (you've bypassed that axis). Still worthwhile for general health.
• NAC: Reduces oxidative stress; may offset polycythemia risk slightly.
• Vitamin D3 & K2: Cardiovascular support; independent benefit, not synergistic with testosterone.
• Omega-3: Lipid support; counters TRT-induced HDL reduction.
• Ashwagandha, berberine: Mood, metabolic support—not testosterone-specific.

None of these amplify TRT efficacy. They're damage control.

The Bottom Line

TRT works—but only in hypogonadal men (testosterone persistently <300 ng/dL and symptoms). Marketing that bypasses this distinction is predatory. "Powerful TRT" without baseline testing, without monitoring, bundled with ED drugs as a marketing package, is not medicine—it's commerce.

If your testosterone is low and symptoms match, TRT is evidence-based. If your testosterone is normal and marketing is selling you "power," you're buying risk masquerading as enhancement.

Demand baseline labs. Insist on monitoring. Be skeptical of claims that outpace the literature.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.